India Medical Devices Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

India Medical Devices Market Trends and Insights

Escalating Burden of Non-Communicable Diseases

Care for noncommunicable diseases creates an equipment requirement that continues after the first screening encounter. By February 2026, India's National Programme for Prevention and Control of Non-Communicable Diseases reported 55.72 million hypertension cases on treatment.^[1] The program also reported 33.93 million diabetes cases on treatment at that point. Its 2023-2030 operational guidelines call for follow-up and monthly drug refills at sub-centers, establishing a continuing local-care pathway. The guideline's local follow-up pathway broadens the relevance of NCD devices beyond hospital departments to teams managing treated cases at sub-centers.

Government Incentives for Domestic Manufacturing

Sales-linked manufacturing incentives can improve the economics of supplying eligible devices from Indian production facilities. The Department of Pharmaceuticals' production-linked incentive scheme provides a 5% incentive on incremental sales of eligible India-manufactured medical devices for 5 years. In September 2026, the department reported that production had commenced for 57 unique devices, including MRI machines, CT scanners, and heart valves. This supported range includes high-end devices that were earlier predominantly imported. Because these categories were earlier predominantly imported, production under the scheme shifts part of the supply base for MRI machines, CT scanners, and heart valves toward Indian facilities.

Expansion of Healthcare Infrastructure and Insurance Coverage

Insurance-backed treatment and neighborhood care infrastructure create complementary routes for expanding the use of medical equipment. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) had more than 38,466 public and private hospitals empaneled across India as of August 12, 2026.^[2] The program had covered a cumulative 126.9 million hospitalizations by June 30, 2026, demonstrating substantial use of its treatment network. More than 186,000 Ayushman Arogya Mandirs were also functional on August 12, 2026, providing neighborhood primary healthcare. Covered admissions connect insurance support to delivered hospital care, while functional primary-care centers establish a separate setting for assessment.

Digital Health Transformation and Telemedicine Adoption

Telemedicine can create an equipment opportunity where diagnostic information helps clinicians assess patients remotely. The Centre for Development of Advanced Computing described implemented diagnostic-device integration for eSanjeevani in its FY2024-25 report. The service operated through over 123,332 spokes and 15,757 hubs during that fiscal year. By September 15, 2026, it had recorded a cumulative 500.1 million teleconsultations across all 36 Indian states and union territories. Device integration connects the equipment opportunity to the clinical information exchanged during remote assessment, giving it a function beyond the consultation link itself.

Stringent Regulatory and Compliance Requirements

Regulatory timelines and compliance expenses make authorization a commercial constraint for device suppliers. In its report presented on August 7, 2026, the parliamentary health committee said it had been given to understand that regulatory delays, administrative redundancies, and high compliance burdens inflated device costs.^[3] It linked the higher final cost of medical devices to weaker healthcare access. Administrative duplication therefore matters alongside review time, because both enter the cost of bringing devices to care providers. Suppliers carry authorization time and compliance expense before a device can earn revenue from authorized sales.

Price Controls and Reimbursement Limitations

Price controls and incomplete reimbursement can constrain access from opposite sides of a device transaction. In its 2026 report, the Rajya Sabha Committee on Petitions said medicine-oriented price controls had reduced margins and, in some cases, prompted high-end device withdrawals in India. The report also recorded the view of a medical institute (SKIMS) that AB-PMJAY coverage for cardiac catheterization had fallen from 100% to 50%, leaving substantial patient expenses. Product withdrawal narrows the choices available to treating teams, making margin pressure relevant to clinical access. In the SKIMS account, patient payment for catheterization limits the usefulness of access to the device alone.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: Therapeutic Production and Monitoring Investment

Therapeutic devices accounted for a 35.16% share of the India medical devices market size in 2026. By July 2026, Meril Life Sciences' Gujarat project under the medical-device production-linked incentive scheme had been commissioned for heart valves, stents, and balloon catheters for percutaneous transluminal coronary angioplasty (PTCA). The commissioned Gujarat project adds domestic production capacity for those therapeutic devices.

Monitoring devices are forecast to be the fastest-growing segment, with an 8.32% CAGR over 2027-2032. In a July 24, 2026, update, the Department of Pharmaceuticals reported actual investment of INR 100.3 million (USD 1.04 million) in BPL Medical Technologies' Karnataka TS 3 project, covering 5 product lines including patient monitoring. The other lines were anesthesia workstations, automated external defibrillators, ECG equipment, and stress-test systems. Patient monitoring sits within this wider domestic equipment investment, connecting its development opportunity to a project spanning several clinical functions.

By Technology Platform: Disposable Scale and Clinical Visualization

Conventional electro-mechanical devices and disposables represented a 42.12% India medical devices market share in 2026. Poly Medicure Ltd. reported distributing its products to more than 8,000 private and government hospitals and nursing homes across India in FY2025. The company also reported 21.57% FY2025 growth in manufactured-product revenue across domestic and export markets, with intravenous cannulas, prefilled syringes, and blood bags among its products. That institutional reach makes distribution capability a competitive asset across several manufactured-product categories.

Augmented / virtual reality (AR / VR) is forecast to be the fastest-growing segment, with an 8.55% CAGR over 2027-2032. KIMS-SUNSHINE Hospitals announced an AR-enabled outpatient service with SKIA at its Begumpet hospital in Hyderabad in 2025. Its platform converted CT and MRI data into interactive 3D visualizations supporting patient education, surgical planning, and consultation. The added clinical function comes after scan acquisition, when CT and MRI data become tools for explaining and planning treatment.

By Therapeutic Application: Cardiac Infrastructure and Neurology Adoption

Cardiology was the largest segment, accounting for 24.01% of device revenue in 2026. Safdarjung Hospital in New Delhi has 4 cardiac catheterization laboratories, including one operating 24 hours for emergency primary angioplasty. Its dedicated biplane electrophysiology laboratory supports complex cardiac rhythm management. The department's equipment consequently serves different clinical requirements, including emergency intervention and specialized rhythm care within a single cardiac service. Because one of the 4 laboratories runs around the clock for emergency primary angioplasty, equipment uptime there is a continuity requirement for heart-attack care.

Neurology is forecast to be the fastest-growing segment, with a 9% CAGR over 2027-2032. Apollo Hospitals Chennai performed adaptive deep brain stimulation for Parkinson's disease on March 2, 2026, in what it described as India's first clinical activation. Orthopedics has a distinct inpatient workload, with Lok Nayak Hospital in New Delhi recording 3,874 orthopedic inpatients in 2025. Apollo Chennai's movement-disorder neurology and functional neurosurgery expertise links the stimulation system to a specialized treatment service, making clinical capability central to replicating that use.

By End-User: Hospital Capacity and Multispecialty Clinics

Hospitals were the largest segment, accounting for 65.13% of device revenue in 2026. As of March 31, 2026, Apollo Hospitals Enterprise Limited had capacity for 10,970 beds across 78 hospitals in India and overseas. An inpatient network of that scale creates an equipment requirement across treatment and patient assessment, giving suppliers several clinical functions to serve within institutional care.

Clinics are forecast to be the fastest-growing segment, with a 9.2% CAGR over 2027-2032. Apollo Clinic inaugurated a facility in Tiruppur, Tamil Nadu, on July 27, 2026, expanding its network in the state. The clinic offers general medicine, obstetrics and gynecology, pediatrics, and dermatology consultations alongside laboratory testing and X-ray services. Consultations across several specialties make laboratory testing and X-ray support shared functions within this outpatient setting.

Regulatory Framework and Outlook

The comparison of selected jurisdictions assesses India's national framework and Maharashtra's delegated state administration from a device manufacturer's perspective. The national rules allocate imports and Class C/D manufacturing to the central authority, while state authorities oversee Class A/B manufacturing and sales across all device classes. Specified Class A non-sterile, non-measuring devices are exempt from licensing when their manufacturer or importer obtains a Central Drugs Standard Control Organization (CDSCO) registration number. An August 2026 amendment also added quality management system wording to the applicable registration provisions.

India's Medium rating reflects central oversight of imports and Class C/D manufacturing, while Maharashtra's Medium rating reflects its Class A/B manufacturing remit and sales enforcement across all device classes. A June 2026 draft supports the Easing outlook, proposing state Class B license-grant cuts from 140 to 115 days, including Maharashtra, and central Class C/D cuts from 105 to 90 days. An August 2026 amendment also removed the separate loan license for sterilization outsourced to a facility holding a valid Medical Devices Rules license. Manufacturers outsourcing sterilization receive a 6-month transition to implement the new labeling requirement, so the removal of the separate loan license takes effect without an immediate relabeling deadline.

Value Chain Stages

The value chain compares revenue from making devices with earnings from maintaining and upgrading installed equipment. In January 2026, Wipro GE Healthcare introduced SIGNA Prime Elite, an MR imaging system made at its Indian manufacturing facility, placing production at the start of that commercial lifecycle. VMMC & Safdarjung Hospital reported medical-equipment procurement for April through June 2026. After equipment enters service, Philips India's maintenance, upgrade, and implementation offerings provide a separate basis for earning from installed devices.

Manufacturing and distribution contribute to initial device-sales revenue, while maintenance and upgrades create fee opportunities after installation. Each additional hardware sale concerns another device, whereas service fees can arise repeatedly from work on equipment already supplied. Distribution coverage and service capability therefore address different constraints, reaching care facilities before sale and sustaining equipment usefulness afterward.

Key Opportunities for Market Participants

The opportunities compare affordable diagnostic supply for public screening with development routes for priority diagnostic and assistive devices. The National Sickle Cell Anaemia Elimination Mission recorded more than 72.4 million screenings among people aged 0 to 40 in tribal-dominated areas of 17 states through July 16, 2026. State health departments used public tendering and price negotiation to procure sickle-cell point-of-care test kits for less than USD 1.21 per test, establishing a concrete unit-price benchmark for that program. The Indian Council of Medical Research's (ICMR) October 2026 calls provide a separate development enabler for priority diagnostic and assistive devices.

Priority-device proposals must come from regular faculty investigators at engineering or technological institutions among the top 25 in the NIRF 2025 Overall Category and cover at least 8 to 10 technologies. Full proposals for both ICMR calls are due November 13, 2026, at 17:00 IST, with development using existing infrastructure and specifically justified upgrades potentially permitted for priority-device projects. The calls fund institution-led development and assessment rather than purchases of finished devices. State-run sickle-cell screening is therefore the nearest-term supplier opening, but the demonstrated tender-price benchmark limits the price a test-kit offer can sustain.